The fund primarily directs at least 80% of its total assets into companies that are leading advancements in the medical sector. Its core investments largely consist of equity instruments. According to the Adviser, "disruptive medicine" companies encompass, but are not limited to, those engaged in fields such as robotic surgical procedures, gene therapy, genomic research, treatments for rare conditions, cutting-edge medical devices and apparatus, immunotherapy, digital healthcare platforms, and initiatives promoting consumer well-being.
